Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Frequently asked questions
What sector does Oncodesign Precision Medicine (ALOPM) operate in?
Oncodesign Precision Medicine belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oncodesign Precision Medicine (ALOPM) current stock price?
As of the latest data, Oncodesign Precision Medicine stock price is €0.33, with a previous close of €0.33.
What is Oncodesign Precision Medicine (ALOPM) current market capitalization?
Oncodesign Precision Medicine market cap is approximately 6.22 million.
What is Oncodesign Precision Medicine (ALOPM) Earnings Per Share (EPS)?
The trailing EPS is €0.30, and the forward EPS is €0.53.
What is Oncodesign Precision Medicine (ALOPM) Price-to-Earnings (P/E) ratio?
Oncodesign Precision Medicine current P/E ratio is 1.09, with a forward P/E of 0.62.
Does Oncodesign Precision Medicine (ALOPM) pay dividends?
No. Oncodesign Precision Medicine does not pay a dividend.
What is Oncodesign Precision Medicine (ALOPM) beta (volatility) score?
Oncodesign Precision Medicine has a beta of -0.306, indicating lower volatility than the overall market.
